Contact Us
Publications
Gene Therapy
Gendicine® (recombinant human p53 adenovirus injection) is an innovative gene therapy drug developed by SiBiono GeneTech Co., Ltd (SiBiono), which owns its full intellectual property. In October 2004, SiBiono successfully obtained the New Drug License, Manufacturing Approval and GMP Certificate from the State Food & Drug Administration of China, becoming the world’s first authority approved gene therapy drug producer. Gendicine provides a novel, safe and effective therapy to fight against tumors. Gendicine is genetically engineered adenovirus, comprising of two functional components: human wild-type p53 tumor suppressor gene and recombinant serotype 5 adenoviral vector. The adenoviral vector acts as the delivery vehicle to carry p53 gene into tumor cells to initiate their apoptosis…
Posted on September 7th, 2009 | Read more
An exclusive interview with Dr. Zhaohui Peng, founder and CEO of Shenzhen SiBiono GeneTech, who has made history by becoming the first Biotech Company approved to market its gene therapy medication ‘Gendicine’. In October 2003, ‘Gendicine’ was approved by the SFDA for treatment of head and neck squamous cell carcinoma (HNSCC), becoming the first gene therapy available to patients.
Posted on September 7th, 2009 | Read more
Researchers at Tufts University (USA) report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells are thought to be the cells that drive tumor formation. Research shows that STAT3 could become a target for cancer therapy, specifically in Glioblastoma multiforme (GBM), a type of malignant and aggressive brain tumor.
Posted on August 29th, 2009 | Read more
Dr Li Ding Gang, MD, PhD.